Gilead Sciences stock gains after narrowing Q2 loss and firming 2026 guidance
Published on 09/07/2026 at 13:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead Sciences stock (ISIN US3755581036) has advanced in recent weeks after the biopharmaceutical company reported a narrower adjusted loss for the second quarter of 2026 and modestly raised its full-year product sales guidance, with investors now valuing the group at about USD 187.22 billion as of September 5, 2026.ZacksCompaniesMarketCap
Q2 2026 results and updated guidance
According to Zacks, Gilead Sciences reported an adjusted loss of USD 6.75 per share for the second quarter of 2026, which was better than the Zacks Consensus Estimate calling for a loss of USD 7.07 per share and marked a sharp reversal from adjusted earnings of USD 2.01 per share in the same period a year earlier.Zacks
The same report notes that Gilead now expects product sales of USD 30.10 billion to USD 30.40 billion in fiscal 2026, slightly above its prior guidance range of USD 30.00 billion to USD 30.40 billion, signaling confidence in the underlying demand despite the current loss-making quarter.Zacks
Investor positioning and valuation backdrop
Market valuation has responded to the latest figures and guidance, with data from CompaniesMarketCap showing that Gilead Sciences carried a market capitalization of USD 187.22 billion as of September 5, 2026, a level that reflects expectations for recovery in earnings and sustained cash generation from its antiviral and oncology portfolio.CompaniesMarketCap
In parallel, performance analysis from Zacks indicates that Gilead Sciences stock has gained about 13.6 percent since the publication of its last earnings report, as of early September 2026, outperforming the broader S&P 500 index over the same period and underlining investors’ constructive stance following the guidance update.Zacks
Analyst view and dividend context
Zacks currently assigns Gilead Sciences a Rank 3 (Hold), implying expectations for an in-line return over the coming months rather than a pronounced outperformance, even after the recent post-earnings rally and the incremental lift to 2026 sales guidance.Zacks
Recent fund-flow commentary from MarketBeat highlights institutional interest, noting that Gilead Sciences reported revenue of USD 7.80 billion in the relevant quarter versus consensus expectations of USD 7.40 billion, an increase of 10.6 percent year over year from USD 7.05 billion, while also maintaining a quarterly dividend of USD 0.82 per share that translates into an annualized payout of USD 3.28 per share and a yield of about 2.2 percent based on recent trading levels.MarketBeat
Key product and therapeutic focus
Gilead Sciences generates the bulk of its revenue from antiviral therapies, notably in HIV and hepatitis C, and continues to invest in expanding indications and next-generation treatments, with the performance of its HIV franchise remaining central to achieving the 2026 product sales guidance range of USD 30.10 billion to USD 30.40 billion highlighted after the Q2 2026 results.Zacks
Stock price and market metrics
While intraday trading in the United States is paused on September 7, 2026 due to the Labor Day market holiday, recent data show that as of September 5, 2026 Gilead Sciences stock was valued at a market capitalization of USD 187.22 billion, anchoring investor expectations for the group’s earnings recovery and providing a reference point for the stock’s current size in the global pharmaceutical sector.CompaniesMarketCap
Gilead Sciences stock at a glance
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Ticker: GILD
- Trading venue: NASDAQ
- Market capitalization: 187.22 billion USD (as of September 5, 2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: S&P 500
